Bharat Biotech acquires licence for GSK’s Shigella vaccine development
GSK has licensed altSonflex1-2-3, its Shigella vaccine candidate, to Bharat Biotech for continued development and distribution in low and middle-income…
All articles by Gullapalli Prasanna
Gullapalli Prasanna
-
-
FDA approves label expansion of AbbVie hepatitis C therapy
The US Food and Drug Administration (FDA) has approved the label expansion of AbbVie’s Mavyret (glecaprevir/pibrentasvir) for treating adults and paediatric…
-
Enterome to advance EO2463 immunotherapy with $19m funding
Enterome has secured $19m in new private funding to progress its EO2463 OncoMimics immunotherapy, targeting indolent non-Hodgkin's lymphoma (iNHL). The…
-
SpliceBio secures $135m for gene therapy development
SpliceBio has closed a Series B financing round, raising $135m for the clinical development of SB-007, its gene therapy candidate…
-
Outlook’s wet AMD treatment accepted by SMC for NHS Scotland
The Scottish Medicines Consortium (SMC) has accepted Outlook Therapeutics’ Lytenava (bevacizumab gamma) for the treatment of wet age-related macular degeneration (wet…
-
EC approves Alnylam’s vutrisiran for ATTR-CM treatment
The European Commission (EC) has approved Alnylam Pharmaceuticals' Amvuttra (vutrisiran) to treat wild-type or hereditary transthyretin amyloidosis with cardiomyopathy (ATTR-CM) in adults.…
-
EC approves AstraZeneca’s acalabrutinib combo for CLL
The European Commission (EC) has approved a fixed-duration regimen of AstraZeneca's Bruton’s tyrosine kinase (BTK) selective inhibitor, Calquence (acalabrutinib) plus…
-
SCHOTT Pharma invests in RTU cartridge capacity expansion
Drug containment and delivery solutions provider SCHOTT Pharma has announced an investment of more than €100m ($114m) to expand its…
-
EC authorises Sydnexis’ paediatric myopia treatment
The European Commission (EC) has granted marketing authorisation to Sydnexis for its low-dose atropine formulation SYD-101, designed to slow the…
-
Bayer subsidiary Vividion secures rights to Werner helicase inhibitor
Bayer subsidiary Vividion Therapeutics has secured exclusive worldwide rights to develop and commercialise VVD-214, the Werner helicase (WRN) covalent inhibitor,…